Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.60 |
| ▸ | ITK | Q08881 | 2/20 | 0.60 |
| ▸ | SYK | P43405 | 7/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222077 | 0.92 | SYK (0.53) | EGFRITKSYKPTK2CDK2 | |
| SCHEMBL1222074 | 0.89 | EGFR (0.65) | EGFRITKSYKPTK2CDK2 | |
| SCHEMBL1222411 | 0.88 | PTK2 (0.52) | EGFRITKSYKPTK2CDK2 | |
| SCHEMBL1221660 | 0.87 | EGFR (0.61) | EGFRITKSYKPTK2CDK2 | |
| SCHEMBL1222071 | 0.86 | EGFR (0.62) | EGFRITKSYKPTK2CDK2 | |
| SCHEMBL1222113 | 0.86 | EGFR (0.68) | EGFRITKSYKPTK2CDK2 | |
| SCHEMBL1221703 | 0.86 | EGFR (0.68) | EGFRITKSYKPTK2CDK9 | |
| SCHEMBL3663623 | 0.84 | EGFR (0.70) | EGFRITKSYKPTK2CDK2 | |
| SCHEMBL1221681 | 0.84 | SYK (0.70) | EGFRITKSYKPTK2CDK2 | |
| SCHEMBL1222061 | 0.83 | EGFR (0.65) | EGFRITKSYKPTK2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | claimed |
| EP-2234986-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2010-10-06 | — | — | EP | claimed |
| WO-2009080638-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-07-02 | — | — | WO | claimed |
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2234986-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080638-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | EGFR 2202/4885ITK 693/4885SYK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.